A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement.

导出 LinkOut

翻译打印收藏纠错

作者： Jorge R,Barrio ^[1] ; Carol S,Marcus ; Joseph C,Hung ; Jennifer S,Keppler

作者单位： Department of Molecular and Medical Pharmacology, The David Geffen UCLA School of Medicine, Los Angeles, CA 90095-6948, USA. Jbarrio@mednet.ucla.edu ^[1]

主题词动物(Animals);药物批准(Drug Approval);人类(Humans);正电子发射断层显像术(Positron-Emission Tomography);危险性评估(Risk Assessment);时间因素(Time Factors);美国(United States);美国食品和药物管理局(United States Food and Drug Administration)

DOI 10.1016/j.mibio.2004.09.003

PMID 15564146

发布时间 2019-08-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Molecular imaging and biology

361-7页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement.

Molecular imaging and biology

相似文献

Molecular imaging and biology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement.

Molecular imaging and biology

相似文献

Molecular imaging and biology

相关期刊

检索历史清除